N-acetylcarnosine lubricant eyedrops possess all-in-one universal antioxidant protective effects of L-carnosine in aqueous and lipid membrane environments, aldehyde scavenging, and transglycation activities inherent to cataracts: a clinical study of the new vision-saving drug N-acetylcarnosine eyedrop therapy in a database population of over 50,500 patients
Controlled trialHumansTopicalWith N-acetylcarnosine (carnosine prodrug) eyedrops
This study tested carnosine together with N-acetylcarnosine (carnosine prodrug) eyedrops. Its results cannot be assigned to carnosine alone. More combination studies.
- Design
- Controlled trial
- Subjects
- database cohort of over 50,500 patients plus a randomised crossover trial (trial n not stated in abstract)
- What was measured
- Antioxidant and anti-glycation activity of L-carnosine and N-acetylcarnosine in aqueous and liposome models; clinical outcomes and tolerability of N-acetylcarnosine eyedrops in cataract and other age-related eye conditions.
What the authors reported
The authors compared the antioxidant and transglycation activity of L-carnosine and N-acetylcarnosine in aqueous and lipid-membrane models and describe newer carnosine analogues. They report a prospective randomised double-masked placebo-controlled crossover trial and a database of more than 50,500 patients treated with N-acetylcarnosine eyedrops, and state the drops were effective and well tolerated for cataract and other age-related eye conditions.
Limits of this study
The authors are affiliated with the company that developed the product. Trial size, endpoints and effect sizes are not given in the abstract. Full text not read.
Source
PubMed 19487926 · doi:10.1097/MJT.0b013e318195e327
Entry checked against PubMed abstract (E-utilities) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.